(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 July 2011 (07.07.2011)

PCT

(10) International Publication Number
WO 2011/082337 A1

(51) International Patent Classification:
A61K 31/52 (2006.01)

(21) International Application Number:
PCT/US2010/062555

(22) International Filing Date:
30 December 2010 (30.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/291,550 31 December 2009 (31.12.2009) US
61/291,554 31 December 2009 (31.12.2009) US
61/291,544 31 December 2009 (31.12.2009) US

(71) Applicants *(for all designated States except US)*: **GALENEA CORP.** [US/US]; 300 Technology Square, Second Floor, Cambridge, MA 02139 (US). **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9 Kanda -Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SUZUKI, Masaki** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **KONDO, Kazumi** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **KURIMURA, Muneaki** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **VALLURU, Krishna, Reddy** [IN/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **TAKAHASHI, Akira** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **KURODA, Takeshi** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **TAKAHASHI, Haruka** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (JP). **FUKUSHIMA, Tae** [JP/US]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (US). **MIYAMURA, Shin** [JP/US]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (US). **GHOSH, Indranath** [IN/US]; 7 Grant Avenue, Belmont, MA 02478 (US). **DOGRA, Abhishek** [IN/US]; 159 Highland Ave, Apt 3, Somerville, MA 02143 (US). **HARRIMAN, Geraldine** [US/US]; 50 S. Arnolda Road, Charlestown, RI 02813 (US). **ELDER, Amy** [US/US]; 15 Westminster Ave., Arlington, MA 02474 (US). **SHIMIZU, Satoshi** [JP/US]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka-shi, Osaka 5410045 (US). **HODGETTS, Kevin, J.** [GB/US]; 35 Middlesex Circle, Apt 6, Waltham, MA 02452 (US). **NEWCOM, Jason, S.** [US/US]; 81 Myrtle St., Norfolk, MA 02056 (US).

(74) Agent: **BEAN, Brian, D.**; Lando & Anastasi LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/082337 A1

(54) Title: THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE

(57) Abstract: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.